-- FactSetが調査したアナリストによると、バイオジェン（BIIB）の平均投資判断は「オーバーウェイト」、平均目標株価は215.86ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Price: $191.38, Change: $-3.00, Percent Change: -1.54%
Related Articles
Australia
Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $478.09, Change: $+11.83, Percent Change: +2.54%
$TMO
Australia
JPMorgan Adjusts Price Target on Royal Caribbean Group to $345 From $341, Maintains Overweight Rating
Royal Caribbean Group (RCL) has an average rating of overweight and mean price target of $345.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $266.70, Change: $+12.69, Percent Change: +5.00%
$RCL
Australia
HSBC Cuts Microsoft Price Target to $571 From $593
Microsoft (MSFT) has an average rating of Buy and mean price target of $562.51, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $403.97, Change: $-20.50, Percent Change: -4.83%
$MSFT